

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85955

Yoshikazu TAKAOKA, et al.

Appln. No.: National Stage Entry of PCT/JP03/11834

Confirmation No.: not yet assigned

Group Art Unit: not yet assigned

Filed: March 11, 2005

Examiner: not yet assigned

For: TRIAZASPIRO[5.5]UNDECANE DERIVATIVES AND DRUGS COMPRISING THE
SAME AS THE ACTIVE INGREDIENT

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of each of the listed documents, in the ISR should accompany the papers received from the International Bureau. However, applicant will be glad to furnish copies upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
National Stage Entry of PCT/JP03/11834


filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of the corresponding International Search Report citing such documents, indicating the degree of relevance found by the International Bureau.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Mark Boland
Registration No. 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 11, 2005

Comp Known 10/527435

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet

1

of

1

Application Number

National Stage Entry of
PCT/JP03/11834

Confirmation Number

Not yet assigned

Filing Date

March 11, 2005

First Named Inventor

Yoshikazu TAKAOKA

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket Number

Q85955

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	01/40227	A1	6/7/2001	Ono Pharmaceutical Co., Ltd.	
		WO	03/35074	A1	5/1/2003	Ono Pharmaceutical Co., Ltd.	
		JP	2002-348288	A	12/4/2002	Ono Pharmaceutical Co., Ltd.	
		WO	02/074770	A1	9/26/2002	Ono Pharmaceutical Co., Ltd.	
		WO	02/074769	A1	9/26/2002	Ono Pharmaceutical Co., Ltd.	
		WO	98/31364	A1	7/23/1998	MERCK & CO., INC.	
		WO	00/14086	A1	3/16/2000	LEUKOSITE, INC. et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		MAEDA, K. et al. , "Novel low molecular weight spirodiketoperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5" , Journal of Biological Chemistry, 276 (37) , pages 35194 to 35200, (2001)	
		International Search Report of PCT/JP03/11834 dated November 18, 2003	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.